The COG study, a phase III, randomised, double blinded trial of gefitinib, a tyrosine kinase inhibitor targeting EGFR, versus placebo in the second line setting of esophageal cancer patients did not demonstrate improvement in overall survival. The gene discussed is EGFR; the disease is esophageal cancer.